long intergenic non-protein coding RNA 2627Genealiases: []
Q-omics provides the consensus-scored LINC02627 profile across patient tissues and cancer cell-line models. LINC02627 expression is associated with patient survival in 14 of 34 cancer types, with the highest sampling consensus in BRCA. Among the 18 cancer types available for tumor–normal comparison, LINC02627 is differentially expressed in 2, with the highest sampling consensus in KIRC. Additionally, LINC02627 RNA expression shows 6,494 significant gene co-expression associations, with the highest sampling consensus in COAD. Together, these results highlight BRCA, KIRC, and COAD as cancer lineages where LINC02627 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC02627 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC02627 survival associations across molecular data types. LINC02627 RNA expression shows survival associations in the most cancer types (14). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC02627 RNA expression–survival associations across cancer types. High LINC02627 expression shows unfavorable associations in BRCA, ESCA, DLBC, KICH, STAD and KIRC. The BRCA Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify BRCA as the clearest survival context for LINC02627 RNA expression.
This table summarizes LINC02627 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 2. The strongest signals are observed in KIRC for RNA.
This table ranks reproducible tumor–normal expression differences for LINC02627. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC02627 shows lower tumor expression in KIRC and higher tumor expression in BRCA. The KIRC box plot shows higher LINC02627 RNA expression in normal versus tumor tissue (log2 FC = −0.057, t-test p < 0.001).
This table shows molecular features associated with LINC02627 in patient tissues and cancer cell lines. In patient samples, LINC02627 shows the broadest associations at the RNA and protein expression levels, with COAD recurring as the lineage with the largest associated feature set.
